Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia - Data from the FACE-SZ cohort.

Humans Caffeine / adverse effects Tea Schizophrenia / drug therapy Coffee Smoking

Caffeine Negative dimension Schizophrenia Sedation

Journal

Journal of psychiatric research

ISSN: 1879-1379

Titre abrégé: J Psychiatr Res

Pays: England

ID NLM: 0376331

Informations de publication

Date de publication:
05 2023

Historique:

received: 08 12 2022

revised: 06 03 2023

accepted: 08 03 2023

medline: 1 5 2023

pubmed: 20 3 2023

entrez: 19 3 2023

Statut: ppublish

Résumé

Caffeine is the most consumed psychoactive substance worldwide. Previous studies suggested higher caffeine consumption in subjects with schizophrenia spectrum disorders (SSD) as well as associations with symptoms, medication and medication side-effects. In a large and well-characterized sample of SSD subjects we explored the association between caffeine consumption and clinical (psychosis related, severity, general health) as well as pharmacological (antipsychotic treatment, sedation potential) variables. Eight hundred four subjects with data on their caffeine (coffee and tea) consumption successively recruited were included in this study. After controlling for potential confounders (demographic variables, smoking) only the negative dimension of psychosis was associated with the amount of caffeine ingested. Less severe negative symptoms were associated with higher caffeine consumption. The effect size of this association was small (partial correlation coefficient = -0.12) but significant.

Identifiants

DOI: 10.1016/j.jpsychires.2023.03.017 PMID: 36934602

pubmed: 36934602

pii: S0022-3956(23)00135-8

doi: 10.1016/j.jpsychires.2023.03.017

pii:

doi:

Substances chimiques

Caffeine 3G6A5W338E

Tea 0

Coffee 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

206-212

Investigateurs

M Andre (M)

C Andrieu-Haller (C)

B Aouizerate (B)

F Berna (F)

O Blanc (O)

E Bourguignon (E)

D Capdevielle (D)

I Chereau-Boudet (I)

J Clauss-Kobayashi (J)

N Coulon (N)

R Dassing (R)

J M Dorey (JM)

C Dubertret (C)

A Esselin (A)

G Fond (G)

F Gabayet (F)

M Jarroir (M)

D Lacelle (D)

M Leboyer (M)

S Leignier (S)

P M Llorca (PM)

J Mallet (J)

E Metairie (E)

T Michel (T)

D Misdrahi (D)

C Passerieux (C)

J Petrucci (J)

B Pignon (B)

P Peri (P)

C Portalier (C)

R Rey (R)

C Roman (C)

B Schorr (B)

F Schürhoff (F)

A Szoke (A)

A Tessier (A)

M Urbach (M)

G Wachiche (G)

A Zinetti-Bertschy (A)

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have declared that there are no conflicts of interest in relation to the subject of this study.